This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto gets approval in EU for use in pediatric patients aged one year or older.
Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
by Zacks Equity Research
Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.
Pfizer Stock Up This Year So Far: What's Going in its Favor?
by Zacks Equity Research
Pfizer's (PFE) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis
by Zacks Equity Research
Amgen (AMGN) submits a supplemental new drug application to the FDA, seeking an approval for once-weekly dosage of its multiple myeloma drug, Kyprolis, combined with dexamethasone (Kd).
5 Reasons Why You Should Add Lilly Stock to Your Portfolio
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Why Is Amgen (AMGN) Up 1.3% Since Last Earnings Report?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test
by Zacks Equity Research
Roche's (RHHBY) cobas EGFR Mutation Test v2 gets FDA nod as a companion diagnostic test with IRESSA.
Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.
Amgen Stock Up This Year So Far: Will the Rally Continue?
by Zacks Equity Research
After a relatively strong performance so far this year, let's see how things are poised for Amgen (AMGN) in the second half of the year.
What's in Store for Amgen (AMGN) in Second Half of 2018?
by Zacks Equity Research
After a relatively strong first half, let's see how things are poised for Amgen (AMGN) in the second half of the year.
Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why
by Zacks Equity Research
Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release
by Zacks Equity Research
Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.
Top Research Reports: UnitedHealth, PepsiCo, Amgen & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 12 major stocks, including UnitedHealth (UNH), PepsiCo (PEP) and Amgen (AMGN).
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2
by Zacks Equity Research
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up
by Zacks Equity Research
Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.
Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Ligand (LGND) beats both earnings and sales estimates in the second quarter of 2018. The company raised its guidance for 2018.
Zacks Investment Ideas feature highlights: Merck and Amgen
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Merck and Amgen
Two Pharma Giants Successfully Navigate a Challenging Climate
by David Borun
Amgen and Merck rely on a wide range of profitable drugs to produce steady profits
Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on lead drug Tymlos' uptake and an update on Radius Health's (RDUS) marketing application for the drug in Europe, when it reports second-quarter results on Aug 7.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Pfizer (PFE) Beats on Q2 Earnings & Sales, Ups Profit View
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings as well as sales in the second quarter. It raises earnings expectations for 2018 but slightly lowers the sales range.
Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales
by Zacks Equity Research
Roche's (RHHBY) performance in the first half is buoyed by solid strength in new drugs like Ocrevus. The increase in guidance is impressive as well.
Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated second-quarter results and raises its outlook for the full year. Shares rise in after-hours trading.